BackImmunityBio Overview

ImmunityBio Net Tangible Assets

Track ImmunityBio's net tangible assets ($-870M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-869.13M

Peer average

Loading

ImmunityBio Net Tangible Assets History

Loading

ImmunityBio vs. peers: Net Tangible Assets Comparison

Loading

ImmunityBio Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImmunityBio (IBRX) FAQ

ImmunityBio (IBRX) currently reports a net tangible assets of $-870M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore ImmunityBio's net tangible assets history and peer comparisons.

ImmunityBio's net tangible assets changed from $0 to $-870M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunityBio reported $-870M in net tangible assets as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $-870M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On net tangible assets, it currently shows $-870M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.